Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Cancer Research

• Publication date

  1994-03-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 8137251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of anthracyclines and related agents that retain preferential activity over Adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A

  2008cited by this paper
• Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles

  2004cited by this paper
• Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity

  1993cited by this paper
• Modulation of doxorubicin resistance in multidrug‐resistant cells by liposomes

  1993cited by this paper
• Quantitative analysis of the lipophilic doxorubicin analogue annamycin in plasma and tissue samples by reversed-phase chromatography.

  1993cited by this paper
• In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.

  1993cited by this paper
• Effect of liposomes on P-glycoprotein function in multidrug resistant cells.

  1992cited by this paper
• Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.

  1992cited by this paper
• Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.

  1992cited by this paper
• Increased accumulation of drugs in multidrug-resistant cells induced by liposomes.

  1992cited by this paper
• Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin.

  1991cited by this paper
• N-(5,5-diacetoxypentyl)doxorubicin: a novel anthracycline producing DNA interstrand cross-linking and rapid endonucleolytic cleavage in human leukemia cells.

  1991cited by this paper
• Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes

  1991cited by this paper
• Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.

  1990cited by this paper
• Anthracycline antibiotics with high liposome entrapment: structural features and biological activity.

  1990cited by this paper
• 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance.

  1990cited by this paper
• 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks.

  1990cited by this paper
• Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes.

  1990cited by this paper
• Immunohistochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation

  1989cited by this paper
• Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin.

  1989cited by this paper
• Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation.

  1989cited by this paper
• P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD.

  1989cited by this paper
• N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.

  1989cited by this paper
• Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.

  1989cited by this paper
• Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin.

  1987influential reference
• Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins.

  1986cited by this paper
• Idarubicin (4-demethoxydaunorubicin)

  1986cited by this paper
• Isolation and genetic characterization of human KB cell lines resistant to multiple drugs

  1985cited by this paper
• Oxyhalogenation of glycals for the synthesis of anti-tumor-active 2'-halo daunorubicin analogs.

  1985cited by this paper
• Intensely potent morpholinyl anthracyclines.

  1984cited by this paper
• Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines.

  1984cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper

• Drug Delivery Nano-Platforms for Advanced Cancer Therapy

  2024cites this paper
• Clinical application and future direction of liposomal assisted drug delivery system

  2022cites this paper
• Liposomal Formulations in Clinical Use: An Updated Review

  2017cites this paper
• Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells

  2017cites this paper
• Advances and Challenges of Liposome Assisted Drug Delivery

  2015cites this paper
• Chapter-4 Preparation and Optimization of Liposomes

  2015cites this paper
• Aerosol Azacytidine Inhibits Orthotopic Lung Cancers in Mice through Its DNA Demethylation and Gene Reactivation Effects

  2014cites this paper
• Natural products as lead compounds in drug discovery

  2013cites this paper
• Synthesis, characterization, and in vitro evaluation of palmitoylated arabinogalactan with potential for liver targeting.

  2013cites this paper
• Epigenetic Control of Tumor Suppressor Genes in Lung Cancer

  2012cites this paper
• Tumor suppressor genes

  2012cites this paper
• Enhancement of doxorubicin-induced antitumor activity and reduction of adverse reactions by cucurbitacin I

  2012cites this paper
• Liposomes a vesicular nanocarrier: potential advancements in cancer chemotherapy.

  2012cites this paper
• Treatment of Acute Lymphoblastic Leukaemia

  2012cites this paper
• doxorubicin in HL-60 leukemia cell lines related multidrug resistance: comparison with idarubicin and The novel anthracycline annamycin is not affected by P-glycoprotein-

  2011cites this paper
• Current trends in liposome research.

  2010cites this paper
• Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity.

  2010cites this paper
• Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.

  2010cites this paper
• From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors.

  2009cites this paper
• Screening of biochemical modulator by tumor cell permeability of doxorubicin.

  2008cites this paper
• Anserine induced advantage effects on the antitumor activity of doxorubicin.

  2007cites this paper
• Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia

  2007cites this paper
• Cross-linked nanoparticles of cytarabine: encapsulation, storage and in-vitro release

  2007cites this paper
• Comparison of artificial neural network and multiple linear regression in the optimization of formulation parameters of leuprolide acetate loaded liposomes.

  2005cites this paper
• Artificial neural network as an alternative to multiple regression analysis in optimizing formulation parameters of cytarabine liposomes.

  2004cites this paper
• WP744 is a novel anthracycline with enhanced activity against neuroblastoma.

  2004cites this paper
• Artificial neural network as an alternative to multiple regression analysis in optimizing formulation parmaeters of cytarabine liposomes

  2004cites this paper
• Increased effects of MPDAX, a novel xanthine derivative, on antitumor activity of doxorubicin.

  2004cites this paper
• Development of new topoisomerase II-targeting compounds as candidate anticancer drugs

  2003cites this paper
• OPTIMIZATION OF FORMULATION PARAMETERS OF CYTARABINE LIPOSOMES USING 33 FACTORIAL DESIGN

  2003cites this paper
• New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity

  2003cites this paper
• Liposome-based approaches to overcome anticancer drug resistance.

  2003cites this paper
• DNA Topoisomerases in Cancer Therapy

  2003cites this paper
• Pharmaceutical biotechnology

  2002cites this paper
• Effects of liposome‐entrapped annamycin in human breast cancer cells: Interference with cell cycle progression and induction of apoptosis

  2001cites this paper
• Methode de traitement du cancer

  2000cites this paper
• Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems.

  1999cites this paper
• Lipophilic drug derivatives in liposomes

  1998cites this paper
• In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin.

  1998cites this paper
• Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma.

  1998cites this paper
• CHAPTER 4.5 – Liposomes as carriers of lipophilic antitumor agents

  1998cites this paper
• Synthesis of (±)-7-(3,4,5-trimethoxyphenyl)-7-deoxyidarubicinone. A new family of anthracycline analogues

  1998cites this paper
• In vivo model systems in P-glycoprotein-mediated multidrug resistance.

  1998cites this paper
• Multidrug-resistant acute leukemia cells are responsive to prolonged exposure of daunorubicin: implications for liposome-encapsulated daunorubicin.

  1998cites this paper
• Synthesis and cytotoxic evaluation of substituted sulfonyl-N-hydroxyguanidine derivatives as potential antitumor agents.

  1997cites this paper
• Annamycin circumvents resistance mediated by the multidrug resistance‐associated protein (MRP) in breast MCF‐7 and small‐cell lung UMCC‐1 cancer cell lines selected for resistance to etoposide

  1997cites this paper
• Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin with Liposomal-Annamycin.

  1997cites this paper
• Anthracyclines in haematology: preclinical studies, toxicity and delivery systems.

  1997cites this paper
• Modifications in high-density lipoprotein lipid composition and structure alter the plasma distribution of free and liposomal annamycin.

  1997cites this paper
• Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients.

  1996cites this paper
• Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: effect of surfactant on liposome formation, stability and size

  1996cites this paper
• The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.

  1996cites this paper
• Comparison of DNA sequence selectivity of anthracycline antibiotics and their 3'-hydroxylated analogs.

  1996cites this paper
• Distribution of free and liposomal annamycin within human plasma is regulated by plasma triglyceride concentrations but not by lipid transfer protein.

  1995cites this paper
• Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity.

  1995cites this paper
• Recent advances in liposomal drug-delivery systems.

  1995cites this paper
• Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance

  1995cites this paper
• Sterically stabilized liposome therapeutics

  1995cites this paper
• Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non‐cross‐resistant anthracycline annamycin incorporated in liposomes

  1995cites this paper
• Partial circumvention of multi‐drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells

  1995cites this paper
• The use of liposomes as carriers of lipophilic anthracycline antibiotics

  1994cites this paper
• Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells

  1994cites this paper
• Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach.

  1993cites this paper